113. Muscular dystrophy Clinical trials / Disease details

Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00577577 (ClinicalTrials.gov)	December 2007	18/12/2007	Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1	A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Safety and Efficacy Endpoints After Administration of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) for 24 Weeks in Adults With Myotonic Dystrophy Type 1	Myotonic Dystrophy Type 1	Drug: rhIGF-I/rhIGFBP-3;Drug: placebo	Insmed Incorporated	Muscular Dystrophy Association	Active, not recruiting	21 Years	65 Years	Both	60	Phase 2	United States
2	NCT00233519 (ClinicalTrials.gov)	November 2005	3/10/2005	Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)	Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)	Myotonic Dystrophy	Drug: SomatoKine/IPLEX	University of Rochester	National Institute of Neurological Disorders and Stroke (NINDS);Imsmed Incorporated	Completed	21 Years	60 Years	All	17	Phase 1/Phase 2	United States